PlasmaGen raises ₹150 crore, valuation crosses ₹1,500 crore
In a significant development in the Indian biotechnology sector, Bengaluru-based PlasmaGen Biosciences has raised ₹150 crore in a funding round led by ViNS Bioproducts. This investment has propelled the company’s valuation to over ₹1,500 crore, cementing its position as a leading player in the industry. With this funding, PlasmaGen has now raised over ₹600 crore to date, backed by prominent investors such as Eight Roads, FIL Capital, and F-Prime.
PlasmaGen Biosciences operates one of India’s five plasma fractionation facilities near Bengaluru, which is a critical component in the production of life-saving therapies. The company’s state-of-the-art facility is equipped to process plasma into various therapeutic products, including immunoglobulins, albumin, and clotting factors. These products are used to treat a range of diseases, including immune disorders, bleeding disorders, and infections.
The funding round led by ViNS Bioproducts is a testament to the growth potential of PlasmaGen Biosciences. The company has been expanding its operations and increasing its production capacity to meet the growing demand for plasma-derived therapies in India and globally. With this investment, PlasmaGen plans to further enhance its manufacturing capabilities, invest in research and development, and explore new markets for its products.
The Indian biotechnology sector has been witnessing significant growth in recent years, driven by government initiatives, increasing demand for healthcare services, and investments from private equity firms. The sector has attracted significant investments from global investors, with many Indian companies emerging as leaders in their respective domains. PlasmaGen Biosciences is one such company that has been at the forefront of this growth, with its commitment to delivering high-quality plasma-derived therapies to patients in India and worldwide.
The company’s strong investor base, including Eight Roads, FIL Capital, and F-Prime, has been instrumental in supporting its growth plans. These investors have a deep understanding of the biotechnology sector and have been actively involved in shaping the company’s strategy. With their support, PlasmaGen has been able to leverage their expertise, network, and resources to drive its expansion plans.
PlasmaGen’s success story is also a reflection of the growing importance of the biotechnology sector in India. The sector has the potential to create significant economic value, generate employment opportunities, and improve healthcare outcomes for patients. The Indian government has been actively promoting the sector through various initiatives, including the establishment of biotechnology parks, funding for research and development, and tax incentives for biotechnology companies.
In conclusion, PlasmaGen Biosciences’ fundraising of ₹150 crore, led by ViNS Bioproducts, is a significant milestone for the company and the Indian biotechnology sector. With a valuation of over ₹1,500 crore, PlasmaGen has emerged as a leading player in the industry, with a strong track record of delivering high-quality plasma-derived therapies to patients. As the company continues to expand its operations and invest in research and development, it is well-positioned to capitalize on the growing demand for biotechnology products in India and globally.
The funding round is also a testament to the growing interest of investors in the Indian biotechnology sector. With its strong growth potential, favorable business environment, and talented workforce, India is emerging as a hub for biotechnology companies. As the sector continues to evolve, we can expect to see more companies like PlasmaGen Biosciences emerging as leaders in their respective domains.
For more information on PlasmaGen Biosciences and its funding round, please visit: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
News Source: https://ascendants.in/funding-feed/plasmagen-biosciences-raises-rs-150-cr/
About the Author
